Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma-Reference-Cited by-同舟云学术

Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma

Published:2019-06-07 Issue:7 Volume:68 Page:1171-1178
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Moya-Plana Antoine^ORCID,Herrera Gómez Ruth Gabriela,Rossoni Caroline,Dercle Laurent,Ammari Samy,Girault Isabelle,Roy Séverine,Scoazec Jean-Yves,Vagner Stephan,Janot François,Eggermont Alexander M. M.,Robert Caroline

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-019-02351-7.pdf

Reference33 articles.

1. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144. https://doi.org/10.1056/NEJMoa1305133

2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690

3. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030. https://doi.org/10.1200/JCO.2013.53.0105

4. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109–1117. https://doi.org/10.1016/S0140-6736(14)60958-2

5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. https://doi.org/10.1056/NEJMoa1503093

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sinonasal Mucosal Melanoma;Surgical Pathology Clinics;2024-08

2. Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes;Frontiers in Immunology;2024-07-30

3. Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes;Cancers;2024-06-28

4. Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature;Case Reports in Oncology;2024-04-20

5. Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center;Current Oncology;2024-01-22